Further analysis between the expression of CCL19 and the survival of patients or TICs in TIME suggested that CCL19 was not only significantly associated with the survival and clinic–pathological characteristics of BC patients, but also participated in the regulation of TIME partly through closely communicating with multiple TICs, including macrophages, T cells, B cells, NK cells, DCs, mast cells and neutrophils. This evidence concerns the gene CCL19 and breast cancer.